Page 1685 - Williams Hematology ( PDFDrive )

1660 Part XI: Malignant Lymphoid Diseases Chapter 100: Mantle Cell Lymphoma 1661

TABLE 100–5. Therapy for Relapsed Mantle Cell Lymphoma
Number of Median PFS Median OS
Author (Year) Phase Patients Regimen ORR% (CR%) (Months) (Months)
Goy (2009) 71 II 141 Bortezomib 33 (8) 7 24 months
Baiocchi (2011) 72 II 13 R-bortezomib 29 (29) 2 NA
Lamm (2011) 73 II 16 R-bortezomib/ 81 (44) 12 39
dexamethasone
Kaufmann (2004) 74 II 16 R-thalidomide 81 (31) 20 75% (3 years)
Zinzani (2013) 75 II 57 Lenalidomide 35 (12) 4 19
Goy (2013) 76 II 134 Lenalidomide 28 88) 4 19
Trneny (2014) 78 II 170 Lenalidomide 40 (5) 9 28
84 monochemotherapy 11 (0) 5 21
Wang (2012) 77 II 44 R-lenalidomide 57 (36) 11 24
Witzig (2005) 79 II 34 Temsirolimus 250 mg 38 (3) 7 (TTP) 12
Ansell (2008) 80 II 27 Temsirolimus 25 mg 41 (4) 6 (TTP) 14
Hess (2009) 81 III 162 Temsirolimus 175/75 22 (2) 5 13
mg 6 (0) 3 10
Temsirolimus 175/25 2 (2) 2 10
mg
chemotherapy
Ansell (2011) 82 II 69 R-temsirolimus 59 (19) 10 30
Renner (2012) 83 II 35 Everolimus 20 (6) 6 NA
Wang (2013) 84 II 111 Ibrutinib 68 (21) 14 NA
Wang (2014) 85 II R-ibrutinib
100 (low Ki-67) 90% (1 year) 90% (1 year)
50 (high Ki-67) 13.6 13.6
Kahl (2014) 86 I 16 Idelalisib 62 (NA) 3 (RD) NA
Davids (2013) 87 I 8 MCL Abt-199 (Venetoclax) 100 NA NA

CR, complete response; NA, not available; ORR, overall response rate; OS, overall survival; PFS progression-free survival; R, rituximab; TTP, time
to progression.

REFERENCES 11. Cuneo A, Bigoni R, Rigolin GM, et al: Cytogenetic profile of lymphoma of follicle man-
tle lineage: Correlation with clinicobiologic features. Blood 93:1372, 1999.
1. Banks PM, Chan J, Cleary ML, et al: Mantle cell lymphoma. A proposal for unification 12. Greiner TC, Moynihan MJ, Chan WC, et al: p53 mutations in mantle cell lymphoma
of morphologic, immunologic, and molecular data. Am J Surg Pathol 16:637, 1992. are associated with variant cytology and predict a poor prognosis. Blood 87:4302,
2. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lym- 1996.
phoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 13. Dreyling MH, Bullinger L, Ott G, et al: Alterations of the cyclin D1/p16-pRB pathway
84:1361, 1994. in mantle cell lymphoma. Cancer Res 57:4608, 1997.
3. Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumours of Haemato- 14. Rosenwald A, Wright G, Wiestner A, et al: The proliferation gene expression signature
poietic and Lymphoid Tissues, ed 4. International Agency for Research on Cancer, Lyon, is a quantitative integrator of oncogenic events that predicts survival in mantle cell lym-
France, 2008. phoma. Cancer Cell 3:185, 2003.
4. Fernàndez V, Salamero O, Espinet B, et al: Genomic and gene expression profiling 15. Hartmann E, Fernàndez V, Moreno V, et al: Five-gene model to predict survival in
defines indolent forms of mantle cell lymphoma. Cancer Res 70:1408, 2010. mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin
5. Tiemann M, Schrader C, Klapper W, et al: European MCL Network: Histopathology, Oncol 26:4966, 2008.
cell proliferation indices and clinical outcome in 304 patients with mantle cell lym- 16. Determann O, Hoster E, Ott G, et al: European Mantle Cell Lymphoma Network and
phoma (MCL): A clinicopathological study from the European MCL Network. Br J the German Low Grade Lymphoma Study Group: Ki-67 predicts outcome in advanced-
Haematol 131:29, 2005. stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy:
6. Fu K, Weisenburger DD, Greiner TC, et al: Cyclin D1-negative mantle cell lymphoma: Results from randomized trials of the European MCL Network and the German Low
A clinicopathologic study based on gene expression profiling. Blood 106:4315, 2005. Grade Lymphoma Study Group. Blood 111:2385, 2008.
7. A clinical evaluation of the International Lymphoma Study Group classification of non- 17. Dreyling M; European Mantle Cell Lymphoma Network: Mantle cell lymphoma: Biol-
Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood ogy, clinical presentation, and therapeutic approaches. Am Soc Clin Oncol Educ Book
89:3909, 1997. 191, 2014.
8. Zhou Y, Wang H, Fang W, et al: Incidence trends of mantle cell lymphoma in the United 18. Romaguera JE, Medeiros LJ, Hagemeister FB, et al: Frequency of gastrointestinal
States between 1992 and 2004. Cancer 113:791, 2008. involvement and its clinical significance in mantle cell lymphoma. Cancer 97:586, 2003.
9. Jares P, Colomer D, Campo E: Genetic and molecular pathogenesis of mantle cell lym- Erratum in: Cancer 97:3131, 2003.
phoma: Perspectives for new targeted therapeutics. Nat Rev Cancer 7:750, 2007. 19. Cheah CY, George A, Giné E, et al: European Mantle Cell Lymphoma Network: Cen-
10. Hirt C, Schuler F, Dolken L, et al: G. Low prevalence of circulating t(11;14) tral nervous system involvement in mantle cell lymphoma: Clinical features, prognostic
(q13;q32)-positive cells in the peripheral blood of healthy individuals as detected by factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol
real-time quantitative PCR. Blood 104:904, 2004. 24:2119, 2013.

Kaushansky_chapter 100_p1653-1662.indd 1660 9/18/15 5:06 PM